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Accepted 14 September 2012AbstractInterstitial cystitis (IC) has been described as a chronic debilitating sterile inflammatory multifactorial bladder syndrome of unknown
etiology. IC is characterized by bladder pain (or suprapubic pain) associated with urgency, urinary frequency, and nocturia. Because the
pathogenesis of IC remains unclear, it is still an enigma and represents a diagnostic and therapeutic challenge. The diagnosis of IC remains
unclear and is based on exclusion of other diseases. Consequently, IC has usually been underdiagnosed, and the consensus on best available
treatment for the disease is lacking. The current goal for the treatment of IC is usually symptomatic relief, and treatment protocols are based on
empiricism. Multiple forms of therapy are available, and most patients can be managed conservatively. Nevertheless, the efficacy of most
treatments is short term. This review article gives an overview of the available treatments for IC.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Interstitial cystitis (IC) has been described as a chronic
debilitating sterile inflammatory multifactorial bladder disease
that results in severe impairment of quality of life (QOL). It is
characterized by bladder pain, urinary frequency, urgency, and
nocturia. In an epidemiologic study in Finland, the prevalence
of IC was estimated to be 18.1 per 100,000 women [1]. Temml
et al [2] considered women with high symptom and problem
scores (12) on the O’LearyeSant IC questionnaire [3] to be
most likely to have IC. The Temml study revealed the overall
prevalence of IC to be 306/100,000 women, with the highest
value (464/100,000) in middle-aged women (40e59 years).
About two-thirds of women with moderate to high risk for IC* Corresponding author. Department of Obstetrics and Gynecology, Fu Jen
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http://dx.doi.org/10.1016/j.tjog.2012.10.002reported an impairment of QOL. In addition, the same study
also showed that 35% of the IC patients reported an effect on
their sexual life. However, the etiology of IC has not yet been
clarified. Hence, IC has usually been underdiagnosed [4], and
the consensus on best available treatment for this condition is
lacking [5]. Treatment options for IC include conservative
treatments, oral medications, intravesical therapy, intravesical
botulinum toxin A injection, hydrodistention (HD), and
surgeries. Oral or intravesical therapies are the mainstay
treatment, whereas surgical managements are reserved for
refractory cases. To date, clinical trials of individual therapies
for IC have been limited in terms of size, quality, and duration
of follow-up [6]. In addition, studies of combination or
multimodal therapies are lacking. Owing to the paucity of
randomized controlled trials (RCTs) on different treatments,
an evidence-based management protocol has not yet been
developed. This article therefore gives an overview of the
treatments for IC in women.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Treatment strategies for IC should begin from more
conservative therapies, and initial treatment type should
depend on patient preferences, symptom severity, and the
clinician’s decision-making. The available conservative ther-
apeutic options for treating IC are numerous, and include
behavior therapy, dietary control, stress reduction, and phys-
ical therapy.
Behavioral therapy including bladder training, controlled
fluid intake, and Kegel exercises improved symptoms in more
than one-half of the IC patients [7,8].
IC patients afflicted with the chronic form of this disease
will usually have a reduced-capacity bladder that is in part
based on their constant urination at low volumes. The bladder
holding protocol dictates keeping a voiding diary, carefully
timing voiding, and gradually increasing the intervals between
voiding. This behavior modification may be helpful in
increasing bladder capacity.
Although controlled studies regarding the effect of dietary
manipulation on IC are lacking, diet control is recommended
as a first-line self-care treatment regimen for IC patients. More
than 50% of IC patients can identify acidic foods that aggra-
vate or cause a relapse in symptoms [9]. Dietary manipulation
by avoiding acidic beverages, caffeine, alcohol, chocolate, tea,
soda, spicy food, and artificial sweetener may be helpful
[10,11]. Once offending foods are suspected, the use of an
elimination diet might identify which foods or fluids
contribute to flare symptoms, and the patient should then be
counseled to avoid said foods [12,13]. However, not all
patients need to try a restricted diet, and not every patient is
sensitive to the same foods. Because many IC patients modify
their diet and are also chronically ill, nutritional supplemen-
tation can be of benefit [10].
Stress is likely the most significant factor that aggravates
the symptoms of IC. Patients should be encouraged to
implement stress reduction techniques. The techniques might
not only be very useful preventative management for patients
in remission but also beneficial to patients with severe
symptoms. For those with severe symptoms, stress reductions
such as lifestyle changes, shortening working hours, choosing
a less demanding workload, exercise, bathing, or joining
support groups could be exceedingly helpful [9,14,15]. In
addition, because psychological and emotional support from
the family is crucial, patient education is necessary to give the
patient and her family a good understanding of IC to help cope
with the disease. Working against such stress reduction
interventions are the stress-creating IC symptoms such as
chronic bladder pain (or pelvic pain), urinary frequency, and
sleep loss due to nocturia. These can cause anxiety and
depression. Remission of these IC symptoms can help to
reduce patient stress.
Physical therapy such as exercising regularly, learning self-
relaxation of the pelvic floor muscles, using biofeedback, and
using maneuvers that resolve pelvic or other connective tissue
pains can help; one can also try the more mental techniques
such as learning meditation [16e18]. Other adjuvanttreatments reported to relieve IC symptoms include acupunc-
ture, hypnosis, and soft tissue massage [19]. However, pelvic
floor strengthening exercises, including Kegel exercises,
should be avoided [20].
Oral medication
Oral pharmacologic therapies remain a mainstay for the
treatment of IC. Oral medications include pentosan polysulfate
sodium (PPS), amitriptyline (Elavil), hydroxyzine (Atarax),
antimuscarinics, cyclosporine A (Cy A), antibacterial agents,
and analgesics. To date, clinical trials of individual therapies
with oral medication have been limited in terms of size,
quality, and duration of follow-up, and studies of combination
or multimodal therapies are lacking [6].
PPS (Elmiron) is the only oral therapy with U.S. Food and
Drug Administration approval for the treatment of IC. The
etiology of IC remains unclear; however, the most frequently
discussed pathologic abnormality used to explain IC is
a defect of the epithelial glycosaminoglycan (GAG) layer that
separates and protects the transitional epithelium from urine
[21]. PPS, a weak heparinoid similar to one of the components
in the GAG layer, is believed to repair the damaged GAG layer
and prevents leakage in the urothelium. It is the first oral
medication for IC that has undergone randomized placebo-
controlled trials [22e25]. Three trials showed modest
symptom improvement [26e28]. However, the results of the
placebo-controlled double-blind trials are contradictory
[23,24,28]. This implies that some IC patients may have
urothelial leakage, but not all IC is due to GAG layer
deficiencies.
Chronic pelvic pain and sleep disturbances may cause
stress in IC patients. Amitriptyline, a tricyclic antidepressant
used to relieve the chronic pain associated with IC, may also
have an effect on sleep disturbances because of its antihista-
mine sedation effects, and thus improve nocturia. van
Ophoven et al [29] showed that amitriptyline provided
symptomatic relief for 15 out of 24 patients in one RCT.
However, the trial did not compare to placebo. Amitriptyline
at different dosages showed a large effect size on standardized
means of pain and urgency scales and on O’LearyeSant
Interstitial Cystitis Symptom Index and frequency [30]. The
patients treated with this medication, starting at 10 to 25 mg
daily, should be given increased dosages to increase the effect
as long as the side effects, including dry mouth and drowsi-
ness, remain tolerable. Long-term administration of amitrip-
tyline is a feasible, safe, and effective treatment for IC
provided that the drug is used judiciously to minimize adverse
effects [31].
Hydroxyzine, a Hi-blocker, involves the theory of pre-
venting mast cell degranulation with the release of neuroactive
and vasoactive chemicals. However, in one RCT, hydroxyzine
failed to show statistically significant benefits over placebo
[32]. In addition, although the combination with PPS
demonstrated a tendency toward a significant effect for the
treatment of IC, there was still no statistical difference in
efficacy as compared with placebo.
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ders. There is a significant overlap between an overactive
bladder and IC symptoms. Nevertheless, the efficacy of anti-
muscarinics for IC patients could be limited because the
pathophysiology of IC and overactive bladder might be
diversely different even if the symptoms overlap.
Cy A is a calcineurin inhibitor that inhibits T cell activation
by blocking the transcription of cytokine genes, among other
functions [33]. Cy A also stabilizes mast cells [34]. Thus, Cy
A is a potent inhibitor of the immune system, and its efficacy
has been reported in the treatment of IC patients [35]. In
a prospective randomized study, Sairanen et al [36] showed
that Cy A is more effective than PPS for the treatment of IC
(with response rates of 75% and 19% for Cy A and PPS,
respectively). However, there were more adverse events in the
Cy A arm than in the PPS arm.
Antibacterial agents are not recommended for the treatment
of IC. In a randomized placebo-controlled study, oral antibi-
otics were shown to have no statistically significant thera-
peutic effect over placebo, and adverse effects occurred more
often in the antibiotics arm [37].
Pain is probably themost frequent driving symptom for an IC
patient to void at lower voiding volume. Low-potency nonste-
roidal anti-inflammatory drugs (NSAIDs) can be used as first-
line analgesics. Other drugs that may be useful are more
potent NSAIDs, cyclooxygenase-2 selective drugs, phenazo-
pyridine (Pyridium), oxybutynin chloride (Ditropan), or opioids.
The use of opioids in urogenital pain is poorly defined. Inter-
esting drugs that are potentially useful in controlling bladder
pain include cannabinoid receptor agonists and purinergic
receptor antagonist compounds. It is important to note that pain
management alone is not considered to be sufficient treatment
for IC and that pain management is just one part of treatment.
Intravesical therapy
Bladder instillation with different agents for the treatment
of IC has been used for decades. The mechanism for this
comprises the existing theories about urothelial dysfunction.
Intravesical pharmacotherapy is one of the mainstays in the
treatment of IC. Intravesical therapy allows the administration
of medication directly into the bladder and achieves a high
drug concentration in the bladder. It also provides a potential
low incidence of systemic side effects due to the relatively
poor absorption from the bladder, provided that the time that
the agent is kept in the bladder is short. Intravesical therapy
could also eliminate the problem of low concentration of
urinary excretion by oral medications and directly target the
urothelium if the pathophysiology of IC is directly related to
urothelial abnormalities. The drugs available for intravesical
therapy are used singly or as a mixture of multiple medications
(as a cocktail). The most commonly used agents include
dimethyl sulfoxide (DMSO), heparin, hyaluronic acid, lido-
caine, PPS, oxybutynin, chondroitin sulfate, steroid, and other
agents mixed as a cocktail. Overall, the evidence base for
treating IC using intravesical preparations is limited, and
RCTs for the treatment of IC are still needed [38].DMSO may be the most commonly used intravesical
agent for IC, and it is the only intravesical therapy since
1978 with U.S. Food and Drug Administration approval for
the treatment of IC. The mechanism of DMSO is not clear
but it supposedly has an anti-inflammatory effect. The drug
is also claimed to work as an analgesic, as a muscle relaxant,
and to promote collagenolysis. The dose of DMSO used
intravesically is 50 mL of a 50% solution instilled into and
retained in the bladder for 10 to 20 minutes, given from one
to two times a week to every few months. In a randomized
double-blind placebo-controlled study, Perez-Marrero et al
[39] showed a marked improvement of symptoms in 53% of
DMSO-treated patients. In a recent study, Rossberger et al
[40] reported that intravesical instillation therapy with
DMSO appears to be a feasible treatment option for both
subtypes of IC with the effect lasting 16e72 months and is
associated with a reasonably low degree of discomfort.
Additional treatments for the relapsed patients would be
needed.
Heparin, an anionic polyelectrolyte, is a GAG derivative.
Intravesical heparin, in a dose of 10,000e20,000 IU in
2e5 mL of solution introduced intravesically for a duration of
1 hour, thrice a week, is used because of the putative GAG
layer deficiency in IC. Parsons et al [41] showed that 56% of
IC patients had their symptoms relieved by heparin. However,
the evidence for intravesical heparin for IC patients is still
limited, and RCTs for the treatment are needed.
Hyaluronic acid, a glycoprotein, is the traditional agent
used for GAG substitution.
Several studies have shown that hyaluronic acid has a place
in the treatment for IC with comparable efficiency and without
significant toxicity [42e44]. In a prospective study recently,
Van Agt et al [45] treated the patients by administration of
40 mg (50 mL) intravesical hyaluronic acid three times weekly
and obtained a positive response rate of 52% after 6 weeks of
treatment.
Intravesical lidocaine (1%), usually 20e30 mL, may be
used. A case report revealed that bladder pain and frequency
could be controlled, but symptoms recurred within 3 months
after treatment [46]. Other studies also reported that lidocaine
instillation relieved pain for only a short term [47,48].
PPS has been administered intravesically and has been
indicated to be effective. Pilot studies suggest a therapeutic
benefit and with earlier responses than those observed with
oral PPS [49]. The use of intravesical PPS simultaneously with
oral PPS has been proposed to be a safe and effective thera-
peutic option [50]. These findings of Davis et al [50] might
open a new option for patients with IC to reduce their
symptom severity and to improve their QOL.
In a randomized trial of intravesical administration of
oxybutynin in combination with bladder training versus
placebo instillation plus bladder training, the oxybutynin
group had a significant increase in bladder capacity, decrease
in urinary frequency, pain relief, and did not have adverse
events [51].
Chondroitin sulfate, a glycoprotein, is a major component
of the GAG layer. GAG layer replenishment is a cornerstone in
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replenishment therapy for IC in the small number of RCTs so
far confirms that chondroitin sulfate (0.2%) is favorable for
intravesical GAG layer replenishment therapy [52]. However,
large-scale trials are urgently needed to further define the
benefit of this type of therapy.
Corticotherapy can be given intravesically because of its
anti-inflammatory effects, and bladder inflammation has been
noted in some patients with IC [53]. Methylprednisolone, from
500 mg to 1 g, can be reconstituted in a small volume of liquid
(10e15 mL) and mixed with DMSO.
Bladder instillation with different agents has been used for
years in an attempt to treat IC. These agents are usually mixed
as a cocktail because there are varying degrees of success for
each drug. The selection of the regimen up to the present has
mainly been based on empiricism. Patients usually undergo
one treatment per week for a 6-week period once the treatment
starts, and the maintenance schedule of treatment depends on
the responses of patients [53].
Other agents that have been used for intravesical treatment
of IC include silver nitrate, Clorpactin, cromolyn sodium,
sodium bicarbonate, resiniferatoxin, and Bacillus Calm-
etteeGuerin (BCG) vaccine. However, resiniferatoxin and
BCG should not be offered to patients because the two drugs
did not show efficacy in well-controlled trials [54,55]. Finally,
the antiproliferative factor protein might be an important
therapeutic target in the future because it might also have an
important role as a urine marker for IC [56].
Intravesical botulinum toxin A injection
Botulinum toxin A, an inhibitor of acetylcholine release at
the presynapse of neuromuscular junction, has well-known
analgesic properties and has demonstrated some benefits in
treating IC pain. The agent has been proved effective for
refractory IC in an open, exploratory study [57]. There are
also several studies that indicated symptom relief in the
treatment of IC with intravesical botulinum toxin A injection,
single or repeated, and did not have significant adverse events
[58e62], However, evidence for botulinum toxin A in the
treatment of IC is limited to small case series. In addition,
a systematic review of reports on the agent for the treatment
of IC concludes that the evidence from the studies so far
suggests a trend toward short-term benefit in refractory
patients, but also noted that further robust evidence should be
awaited [63].
Hydrodistention
HD is recommended for the treatment of IC. The efficacy
of HD of the bladder in the treatment of IC has been known
since the first report appeared in 1930 [64]. Although the
therapy has been the most common treatment for IC since
then, there has been no randomized comparative study. The
proportion of patients who, after bladder HD, show improve-
ment and the duration of any such improvement remain
uncertain. The report by Bumpus [64] in 1930 showed that HDimproved the symptoms of IC and, as a result, this procedure
has become a mainstay of IC patients’ therapy. Most reports
showed that IC symptoms in patients are improved following
HD, but they suggest that the benefits are short-lived [65e68].
Furthermore, a study reported that HD provided little useful
information above and beyond what was available from the
patient’s history and physical examination findings [69]. In
addition, reports on the use of prolonged bladder HD for the
treatment of patients with IC remain controversial [70,71].
Nevertheless, Hsieh et al [72] showed that HD followed by
bladder training, when there was good patient compliance, was
able to produce both a good efficacy and long-term benefits
[72]. There is no standard method for HD, nor is there
a significant difference in efficacy among current HD methods.
The safest method is to fill the bladder with normal saline to
maximal capacity at a pressure of 80 cm H2O, at which point
the full bladder is emptied immediately, without repetition of
the procedure. Bladder rupture and sepsis may be associated
with HD, especially when high-pressure, long-duration HD
has been offered [66,70,71].
Surgery
The role of major surgery in patients with IC is not fully
established. Surgical intervention is not a mainstay in the
treatment of IC symptoms and should be considered the last
resort for severe IC refractory to other therapies. Before
surgery, the patient should be informed of all surgical proce-
dures and should understand the possible outcomes and
possible side effects of this type of intervention.
Less invasive surgeries to treat IC include sacral neuro-
modulation to control the symptoms of IC. Sacral neuro-
modulation should be considered before any major invasive
surgical intervention is undertaken and after conservative
therapies have failed. Several retrospective studies indicate
that sacral neuromodulation provides an effective long-term
outcome [73e76]. The use of the neodymiumeyttrium
aluminum garnet (YAG) laser to fulgurate Hunner’s ulcers to
alleviate IC symptoms has been reported; however, repeated
treatment is usually required [77,78].
The major surgical interventions that have been described
to treat IC include bladder augmentation, urinary diversion,
and cystectomy [79e86]. Although some studies have re-
ported that major surgery is associated with good symptom
relief in strictly selected patients with disabling IC, surgical
intervention for IC has been demonstrated to be of limited use
and failed to achieve long-term remission of symptoms in the
majority of patients.
Conclusion
IC is a complex disease with a constellation of symptoms
such as urinary urgency, urinary frequency, and pelvic pain
affecting urine storage in the bladder. Many physicians still do
not believe that IC exists because IC remains a mysterious
syndrome in female urology. In addition, limited evidence
exists for the few IC treatment options available to doctors.
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patient. Patients should first be encouraged to implement stress
management practice to manage and to cope with symptom
exacerbations induced by stress.
Because the etiology of IC is thought to be multifactorial,
multimodal therapies might be considered if the initial treat-
ment does not result in a significant remission of symptoms. In
addition, the predisposing etiologies inducing the development
of IC should all be ruled out. In women, uterine prolapse may
cause bladder compression, and the long-term effect of the
pathophysiology of uterusebladder compression may result in
a reduced-capacity bladder. Furthermore, the bladder may
enter a status of disuse and atrophy. The famous words “use or
disuse” by La March, a French biologist (1744e1829), may
help to explain the reduced bladder capacity of IC patients.
Hence, it is important to first help reconstruct the pelvis,
especially with uterine suspension when uterine prolapse has
occurred, before the bladder problems in IC patients are
treated.
The “gold standard” IC treatment of cystoscopy with HD is
now being questioned. However, the majority of reports about
HD for IC patients revealed a short-term effect. This fact
reveals that HD is a good method to enlarge the bladder, but
IC patients could not keep their enlarged bladder for a long
time after treatment. Bladder training may be an option to
help post-HD IC patients to reverse their bladder from a state
of disuse/atrophy into a functional state and to create
a bladder big enough to obtain a long-term effect [72]. The
theory about HD plus bladder training keeping the bladder
large for the long term is similar to consciously sitting up
straight in order to correct one’s posture. The simultaneous
implementation of HD and bladder training is important in
order to achieve long-term remission among IC patients.
Hence, HD of the bladder and concomitant bladder training
should be recommended as the first treatment choice for
patients with IC, once IC is suspected, because it provides
significant remission, is a conservative therapy, and avoids
extirpative surgeries.References
[1] Oravisto KJ. Epidemiology of interstitial cystitis. Ann Chirur Gynaecol
Fenn 1975;64:75e7.
[2] Temml C, Wehrberger C, Riedl C, Ponholzer A, Marszalek M,
Madersbacher S. Prevalence and correlates for interstitial cystitis symp-
toms in women participating in a health screening project. Eur Urol 2007;
51:803e8.
[3] O’Leary MP, Sant GR, Fowler Jr FJ, Whitmore KE, Spolarich-Kroll J.
The interstitial cystitis symptom index and problem index. Urology 1997;
49:58e63.
[4] Parsons CL. Interstitial cystitis. In: Ostergard DR, Bent AE, editors.
Urogynecology and urodynamics. Theory and practice. 4th ed. Balti-
more, MD: Williams & Wilkins; 1996. p. 409e25.
[5] Propert KJ, Payne C, Kusek JW, Nyberg LM. Pitfalls in the design of
clinical trials for interstitial cystitis. Urology 2002;60:742e8.
[6] French LM, Bhambore N. Interstitial cystitis/painful bladder syndrome.
Am Fam Physician 2011;83:1175e81.
[7] Chaiken DC, Blaivas JG, Blaivas ST. Behavioral therapy for the treat-
ment of refractory interstitial cystitis. J Urol 1993;149:1445e8.[8] Parsons CL, Koprowski PF. Interstitial cystitis: successful management
by increasing urinary voiding intervals. Urology 1991;37:207e12.
[9] Koziol JA, Clark DC, Gittes RF, Tan EM. The natural history of inter-
stitial cystitis: a survey of 374 patients. J Urol 1993;149:465e9.
[10] Whitmore KE. Self-care regimens for patients with interstitial cystitis.
Urol Clin North Am 1994;21:121e30.
[11] Shorter B, Lesser M, Moldwin RM, Kushner L. Effect of comestibles on
symptoms of interstitial cystitis. J Urol 2007;178:145e52.
[12] Webster DC, Brennan T. Self-care strategies used for acute attack of
interstitial cystitis. Urol Nurs 1995;15:86e93.
[13] Erickson DR, Davies MF. Interstitial cystitis. Int Urogynecol J 1998;9:
174e83.
[14] Webster DC, Brennan T. Self-care effectiveness and health outcomes in
women with interstitial cystitis: implications for mental health clinicians.
Iss Ment Health Nurs 1998;19:495e519.
[15] Rothrock NE, Lutgendorf SK, Kreder KJ, Ratliff T, Zimmerman B.
Stress and symptoms in patients with interstitial cystitis: a life stress
mode. Urology 2001;57:422e7.
[16] Weiss JM. Pelvic floor myofascial trigger points: manual therapy for
interstitial cystitis and the urgencyefrequency syndrome. J Urol 2001;
166:2226e31.
[17] Markwell SJ. Physical therapy management of pelvi/perineal and peri-
anal pain syndromes. World J Urol 2001;19:194e9.
[18] Lukban JC, Whitmore KE. Pelvic floor muscle re-education treatment of
the overactive bladder and painful bladder syndrome. Clin Obstet
Gynecol 2002;45:273e85.
[19] Oyama IA, Rejba A, Lukban JC, Fletcher E, Kellogg-Spadt S,
Holzberg AS, et al. Modified Thiele massage as therapeutic intervention
for female patients with interstitial cystitis and high-tone pelvic floor
dysfunction. Urology 2004;64:862e5.
[20] Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D,
FitzGerald MP, et al. AUA guideline for the diagnosis and treatment of
interstitial cystitis/bladder pain syndrome. J Urol 2011;185:2162e70.
[21] Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H. Bladder surface
glycosaminoglycans: an epithelial permeability barrier. J Urol 1990;143:
139e42.
[22] Parsons CL, Mulholland SG. Successful therapy of interstitial cystitis
with pentosanpolysulfate. J Urol 1987;138:513e6.
[23] Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan
polysulfate sodium for therapy of interstitial cystitis. A double-blind
placebo-controlled clinical study. Urology 1990;35:552e8.
[24] Holm-Bentzen M, Jacobsen F, Nerstrøm B, Lose G, Kristensen JK,
Pedersen RH, et al. A prospective double-blind clinically controlled
multicenter trial of sodium pentosanpolysulfate in the treatment of
interstitial cystitis and related painful bladder disease. J Urol 1987;138:
503e7.
[25] Parsons CL. Current strategies for managing interstitial cystitis. Expert
Opin Pharmacother 2004;5:287e93.
[26] Parsons CL, Schmidt JD, Pollen JJ. Successful treatment of interstitial
cystitis with sodium pentosanpolysulfate. J Urol 1983;130:51e3.
[27] Fritjofsson A, Fall M, Juhlin R, Persson BE, Ruutu M. Treatment of ulcer
and nonulcer interstitial cystitis with sodium pentosanpolysulfate:
a multicenter trial. J Urol 1987;138:508e12.
[28] Parsons CL, Benson G, Childs SJ, Hanno P, Sant GR, Webster G. A
quantitatively controlled method to study prospectively interstitial
cystitis and demonstrate the efficacy of pentosanpolysulfate. J Urol 1993;
150:845e8.
[29] van Ophoven A, Pokupic S, Heineke A, Hertle L. A prospective,
randomized, placebo controlled, double-blind study of amitriptyline for
the treatment of interstitial cystitis. J Urol 2004;172:533e6.
[30] Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel JC, Proietti S,
et al. Contemporary management of the painful bladder: a systematic
review. Eur Urol 2012;61:29e53.
[31] Hertle L, van Ophoven A. Long-term results of amitriptyline treatment
for interstitial cystitis. Aktuelle Urol 2010;41(Suppl. 1):S61e5.
[32] Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, et al.
A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in
patients with interstitial cystitis. J Urol 2003;170:810e5.
531C.-H. Hsieh et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 526e532[33] Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immuno-
pharmacology 2000;47:119e25.
[34] Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W,
Huang SK, et al. The human mast cell: functions in physiology and
disease. Front Biosci 2001;6:1109e27.
[35] Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with
interstitial cystitis treated with low dose cyclosporine A. J Urol 2004;
171:2138e41.
[36] Sairanen J, Tammela TL, Leppilahti M, Multanen M, Paananen I,
Lehtoranta K, et al. Cyclosporine A and pentosan polysulfate sodium for
the treatment of interstitial cystitis: a randomized comparative study.
J Urol 2005;174:2235e8.
[37] Warren JW, Horne LM, Jebel JR, Marvel RP, Keay SK, Chai TC. Pilot
study of sequential oral antibiotics for the treatment of interstitial cystitis.
J Urol 2000;163:1685e8.
[38] Dawson TE, Jamison J. Intravesical treatments for painful bladder
syndrome/interstitial cystitis. Cochrane Database Syst Rev 2007
(4):CD006113.
[39] Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl
sulfoxide in interstitial cystitis. J Urol 1988;140:36e9.
[40] Rossberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide
treatment for interstitial cystitis: discomfort, side-effects and treatment
outcome. Scand J Nephrol 2005;39:73e7.
[41] Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial
cystitis with intravesical heparin. Br J Urol 1994;73:504e7.
[42] Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Treatment of interstitial
cystitis with Cystistat: a hyaluronic acid product. Scand J Urol Nephrol
2005;39:143e7.
[43] Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME. Hyaluronic acid:
an effective alternative treatment of interstitial cystitis, recurrent
urinary tract infections, and hemorrhagic cystitis? Eur Urol 2007;51:
1534e40.
[44] Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pfluger H. Hyaluronan
treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol
J 2008;19:717e21.
[45] Van Agt S, Gobet F, Sibert L, Leroi AM, Grise P. Treatment of interstitial
cystitis by intravesical instillation of hyaluronic acid: a prospective study
on 31 patients. Prog Urol 2011;21:218e25.
[46] Asklin B, Cassuto J. Intravesical lidocaine in severe interstitial cystitis:
case report. Scand J Urol Nephrol 1989;23:311e2.
[47] Rosamilia A, Dwyer PL, Gibson J. Electromotive drug administration of
lidocaine and dexamethasone followed by cystodistension in women with
interstitial cystitis. Int Urogynecol J 1997;8:142e5.
[48] Gurpinar T, Wong HY, Griffith DP. Electromotive administration of
intravesical lidocaine in patients with interstitial cystitis. J Endourol
1996;10:443e7.
[49] Sant GR, LaRock DR. Standard intravesical therapies for interstitial
cystitis. Urol Clin North Am 1994;21:73e83.
[50] Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ. Safety and
efficacy of the use of intravesical and oral pentosan polysulfate sodium
for interstitial cystitis: a randomized double-blind clinical trial. J Urol
2008;179:177e85.
[51] Barbalias GA, Liatsikos EN, Athanasopoulos A, Nikiforidis G. Intersti-
tial cystitis: bladder training with intravesical oxybutynin. J Urol 2000;
163:1818e22.
[52] Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer
replenishment therapy for chronic forms of cystitis with intravesical
glycosaminoglycans d a review. Neurourol Urodyn 2012. http://
dx.doi.org/10.1002/nau.22256.
[53] Swift SE, Chai TC, Bent AE. Painful conditions of the lower urinary
tract including painful bladder syndrome. In: Bent AE, Cundiff GW,
Swift SE, editors. OSTERGARD’S urogynecology and pelvic floor
dysfunction. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins;
2008. p. 106e32.
[54] Mayer R, Propert KJ, Peters KM, Payne CK, Zhang Y, Burks D, et al.
Interstitial Cystitis Clinical Trials Group. A randomized controlled trial
of intravesical bacillus CalmetteeGuerin for 12 treatment refractory
interstitial cystitis. J Urol 2005;173:1186e91.[55] Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE,
Antoci JP, et al. Intravesical resiniferatoxin for the treatment of inter-
stitial cystitis: a randomized, double-blind, placebo controlled trial.
J Urol 2005;173:1590e4.
[56] Keay S, Kaczmarek P, Zhang CO, Koch K, Szekely Z, Barchi Jr JJ, et al.
Normalization of proliferation and tight junction formation in bladder
epithelial cells from patients with interstitial cystitis/painful bladder
syndrome by D-proline and D-pipecolic acid derivatives of anti-
proliferative factor. Chem Biol Drug Des 2011;77:421e30.
[57] Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal
injection of botulinum toxin A in patients with refractory bladder pain
syndrome/interstitial cystitis. Eur Urol 2010;58:360e5.
[58] Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB,
Chancellor MB. Botulinum toxin A has antinociceptive effects in treating
interstitial cystitis. Urology 2004;64:871e5.
[59] Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V,
Porena M. Botulinum A toxin intravesical injections in the treatment of
painful bladder syndrome: a pilot study. Eur Urol 2006;49:704e9.
[60] Liu HT, Kuo HC. Intravesical botulinum toxin A injections plus hydro-
distension can reduce nerve growth factor production and control bladder
pain in interstitial cystitis. Urology 2007;70:463e8.
[61] Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E.
Botulinum A toxin intravesical injection in patients with painful bladder
syndrome: 1-year follow up. J Urol 2008;179:1031e4.
[62] de Miquel F, Chancellor MB. Pittsburgh experience with botulinum toxin
A injection. Actas Urol Esp 2006;30:310e4.
[63] Tirumuru S, Al-Kurdi D, Latthe P. Intravesical botulinum toxin A
injections in the treatment of painful bladder syndrome/interstitial
cystitis: a systematic review. Int Urogynecol J 2010;21:1285e300.
[64] Bumpus HJ. Interstitial cystitis: its treatment by over-distention of the
bladder. Med Clin North Am 1930;13:1495e8.
[65] Hanno PM, Wein AJ. Conservative therapy of interstitial cystitis. Semin
Urol 1991;9:143e7.
[66] Yamada T, Murayama T, Andoh M. Adjuvant hydrodistension under
epidural anesthesia for interstitial cystitis. Int J Urol 2003;10:463e8.
[67] Tomoe H, Kobayashi H, Nakazawa H, Toma H. The efficacy of hydro-
distention of the bladder for interstitial cystitis. J Interst Cyst 2004;2:
24e31.
[68] Parsons M, Toozs-Hobson P. The investigation and management of
interstitial cystitis. J Br Menopause Soc 2005;11:132e9.
[69] Ottem DP, Teichman JMH. What is the value of cystoscopy with
hydrodistension for interstitial cystitis? Urology 2005;66:494e9.
[70] McCahy PJ, Styles RA. Prolonged bladder distention: experience in the
treatment of detrusor overactivity and interstitial cystitis. Eur Urol 1995;
28:325e7.
[71] Glemain P, Riviere C, Lenormand L, Karam G, Bouchot O, Buzelin JM.
Prolonged hydrodistention of the bladder for symptomatic treatment of
interstitial cystitis: efficacy at 6 months and 1 year. Eur Urol 2002;41:
79e84.
[72] Hsieh CH, Chang ST, Hsieh CJ, Hsu CS, Kuo TC, Chang HC, et al.
Treatment of interstitial cystitis with hydrodistention and bladder
training. Int Urogynecol J 2008;19:1379e84.
[73] Maher CF, Carey MP, Dwyer PL, Schluter PL. Percutaneous sacral nerve
root neuromodulation for intractable interstitial cystitis. J Urol 2001;165:
884e6.
[74] Peters KM. Neuromodulation for the treatment of refractory interstitial
cystitis. Rev Urol 2002;4:S36e43.
[75] Gajewski JB, Al-Zahrani AA. The long-term efficacy of sacral neuro-
modulation in the management of intractable cases of bladder pain
syndrome: 14 years of experience inone centre.BJU Int 2011;107:1258e64.
[76] Ghazwani YQ, Elkelini MS, Hassouna MM. Efficacy of sacral neuro-
modulation in treatment of bladder pain syndrome: long-term follow-up.
Neurourol Urodyn 2011;30:1271e5.
[77] Shanberg AM, Baghdassarian R, Tansey LA. Treatment of interstitial
cystitis with neodymiumeYAG laser. J Urol 1985;134:885e8.
[78] Rofeim O, Hom D, Freid RM, Moldwin RM. Use of the neo-
dymium:YAG laser for interstitial cystitis: a prospective study. J Urol
2001;166:134e6.
532 C.-H. Hsieh et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 526e532[79] Nielsen KK, Kromann-Andersen B, Steven K, Hald T. Failure of
combined supratrigonal cystectomy and Mainz ileocecocystoplasty
in intractable interstitial cystitis: is histology and mast cell count
a reliable predictor for the outcome of surgery? J Urol 1990;144:
255e8.
[80] KontturiMJ, Hellstrom PA, Tammela TL, Lukkarinen OA. Colocystoplasty
for the treatment of severe interstitial cystitis. Urol Int 1991;46:50e4.
[81] Irwin PP, Galloway NT. Surgical management of interstitial cystitis. Urol
Clin North Am 1994;21:145e51.
[82] Linn JF, Hohenfellner M, Roth S, Dahms SE, Stein R, Hertle L, et al.
Treatment of interstitial cystitis: comparison of subtrigonal and supra-
tigonal cystectomy combined with orthotopic bladder substitution. J Urol
1998;159:774e8.[83] Peeker R, Aldenborg F, Fall M. The treatment of interstitial cystitis with
supratrigonal cystectomy and ileocystoplasty: difference in outcome
between classic and nonulcer disease. J Urol 1998;159:1479e82.
[84] van Ophoven A, Oberpenning F, Hertle L. Long-term results of trigone-
preserving orthotopic substitution enterocystoplasty for interstitial
cystitis. J Urol 2002;167:603e7.
[85] Rossberger J, Fall M, Jonsson O, Peeker R. Long-term results of
reconstructive surgery in patients with bladder pain syndrome/interstitial
cystitis: subtyping is imperative. Urology 2007;70:638e42.
[86] Andersen AV, Granlund P, Schultz A, Talseth T, Hedlund H, Frich L.
Long-term experience with surgical treatment of selected patients with
bladder pain syndrome/interstitial cystitis. Scand J Urol Nephrol 2012;
46:284e9.
